SES - Delayed Quote SGD

Hyphens Pharma International Limited (1J5.SI)

0.2750 0.0000 (0.00%)
At close: 11:36 AM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SGD.
NameTitlePayExercisedYear Born
Mr. See Wah Lim Executive Chairman & CEO -- -- 1969
Mr. Yufan Zhang Chief Financial Officer -- -- --
Mr. Yann Alain Marche Chief Operating Officer -- -- --
Jessica Tan Chief People Officer -- -- --
Ms. Stella Ang Head of Regulatory Affairs -- -- --
Mr. Jamal Iflizar Country Head of Indonesia -- -- --
Mr. Ang Francis Country Head of Malaysia -- -- --
Josiephine Sac Mantoya Country Head of Philippines -- -- --
Laurence Fremy Country Head of Vietnam -- -- --
Ms. Sher Mei Lim C.A. Company Secretary -- -- --

Hyphens Pharma International Limited

16 Tai Seng Street
Level 4
Singapore, 534138
Singapore
65 6338 8551 https://www.hyphensgroup.com
Sector: 
Healthcare
Full Time Employees: 
422

Description

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine through distributorship or licensing, and supply agreements for the therapeutic areas, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, family medicine, and general surgery. The Proprietary Brands segment develops, markets, and sells dermatological products and health supplement products. This segment offers dermocosmetic products under the Ceradan and TDF brands through medical professionals; health supplement products under the Ocean Health brand directly to consumers via retail channels; and scalp care products under the CG 210 brand through medical professionals. The Medical Hypermart and Digital segment wholesales pharmaceuticals and medical supplies for healthcare professionals and institutions, and retail pharmacies through tele-sales and sales representatives. The segment also operates an online B2B platform; and WellAway, an e-pharmacy. In addition, it offers PLINEST and NEWEST Polynucleotides-HPTTM products; OXITHION, a skin brightening solution; and Nabota, a highpurity botulinum toxin. Further, the company provides pharmaceutical products, nutraceuticals, and medical devices for hospitals, polyclinics, specialists, and general practitioners. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.

Corporate Governance

Hyphens Pharma International Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Feb 27, 2024
Hyphens Pharma International Limited Earnings Call

May 08, 2024

Ex-Dividend Date